Sacubitril or valsartan versus standard medical therapies in patients with heart failure with preserved ejection fraction: PARALLAX trial
1. In this randomized, controlled trial, for patients with heart failure and left ventricular ejection fraction higher than 40%, sacubitril/valsartan ...